ClinicalTrials.gg
RecruitingNCT07423728CHRONO-MOBILIZUpdated Oct 29, 2026

CHRONO-MOBILIZE: Chronotherapy of G-CSF for CD34+ Mobilization in Healthy Donors

An interventional study of G-CSF (Granulocyte colony-stimulating factor) in Granulocyte Colony-Stimulating Factor (G-CSF) Mobilization, sponsored by First Affiliated Hospital of Zhejiang University. Recruiting at 3 sites in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by First Affiliated Hospital of Zhejiang University · Not applicable, Interventional, and Other

How we know

Updated Oct 29, 2026Start date movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Healthy donors are commonly mobilized with granulocyte colony-stimulating factor (G-CSF) to collect peripheral blood stem cells for allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the efficiency of mobilization varies among donors, and suboptimal mobilization may require additional collection procedures or rescue strategies. This prospective, multicenter, randomized trial evaluates whether the timing of daily G-CSF administration (morning vs evening) affects the level of circulating CD34+ cells in healthy donors. Participants will be randomly assigned to receive subcutaneous G-CSF once daily for 4-5 consecutive days either at 08:00 (±15 minutes) or at 20:00 (±15 minutes). The goal of the study is to identify a practical dosing schedule that may improve stem cell mobilization and streamline donor collection procedures.

The study protocol was substantially amended following approval by the Institutional Review Board. The amendments included revisions to the G-CSF administration regimen, the primary and secondary outcome measures, and the assessment schedule. Enrollment under the revised protocol commenced on 1st Nov. Participants enrolled under the previous protocol version will be documented separately and will not be included in the prespecified primary analysis of the revised-protocol cohort.

Read the detailed description

Background and Rationale

Peripheral blood stem cell collection after G-CSF mobilization is the most widely used donation approach for allo-HSCT. Donor mobilization outcomes exhibit inter-individual variability, and donors with lower circulating CD34+ levels may require longer processing volumes, additional collection days, or rescue mobilization. Circadian biology may influence hematopoietic cell trafficking and cytokine responses, suggesting that the administration timing of G-CSF could affect mobilization intensity and collection efficiency. This trial tests whether a simple, operational change in dosing time can improve pre-apheresis CD34+ levels in healthy donors.

Study Design

This is a prospective, multicenter, stratified randomized controlled trial with two parallel arms. The study is open-label due to the nature of the intervention (fixed dosing times), while the statistician will remain blinded to group allocation until database lock. Allocation is stratified by donor age (\<40 vs ≥40 years) and sex to balance key donor characteristics across arms.

Interventions and Procedures

Eligible healthy donors will receive subcutaneous G-CSF at 10 μg/kg once daily for 4-5 consecutive days (Day 1 to Day 5, according to the first day collection efficacy), assigned to one of the following schedules:

Morning group: 08:00 (±15 minutes) each day

Evening group: 20:00 (±15 minutes) each day

The first apheresis session is scheduled to begin after the forth G-CSF dose. Collection targets are based on recipient weight, with standard operational procedures for conducting a second collection day if the first-day yield does not meet the target. If peripheral blood CD34+ is low after the final G-CSF dose, centers may apply rescue mobilization per local practice, and such use will be recorded for sensitivity analyses.

Outcome Measures Primary Outcome: To compare peripheral blood CD34+ cell counts (cells/μL) between healthy donors receiving morning (08:00) versus evening (20:00) G-CSF administration, measured at a standardized clock time of 11:30 (±15 minutes), after the fourth G-CSF dose and immediately before the first apheresis session.

Sample Size and Analysis Overview A total of 160 donors (80 per group) will be enrolled to provide adequate power for detecting clinically meaningful differences in the primary endpoint while allowing for non-evaluable cases. The primary analysis will follow the intention-to-treat principle, with additional per-protocol and sensitivity analyses as appropriate, including analyses accounting for rescue mobilization when applicable.

Safety Monitoring and Follow-up Donors will be monitored with clinical assessment and routine laboratory testing during the mobilization period and on collection days. Adverse events commonly associated with G-CSF (e.g., bone pain) and donation-related events will be recorded and managed per standard-of-care practices. Donors will be followed through approximately Day 30 to capture delayed or persistent adverse events.

02

Conditions studied

  • Granulocyte Colony-Stimulating Factor (G-CSF) Mobilization

Keywords

  • CD34
  • G-CSF
  • Allo-HSCT
03

In context

Lead sponsor

First Affiliated Hospital of Zhejiang University is the lead sponsor of 264 studies on the registry; 145 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-55 years
  2. HLA matching appropriate for intended recipient and meets donor medical evaluation criteria
  3. Body weight ≥35 kg and adequate blood volume/BSA for apheresis
  4. score ≥80
  5. Screening labs meet thresholds (//ANC, liver/renal/coagulation), no splenomegaly, pregnancy test negative if applicable
  6. Written
  7. Stable circadian rhythm before mobilization (no night shift/no ≥3 time-zone travel; avoid melatonin/sedatives or other agents affecting sleep/circadian rhythm)

Exclusion criteria

Exclusion Criteria:

  1. Prior/current hematologic or immune diseases (e.g., aplastic anemia, leukemia, lymphoma, disease)
  2. Significant cardiovascular/structural heart disease, uncontrolled hypertension, uncontrolled diabetes
  3. Neurologic/psychiatric disorders affecting adherence
  4. Sleep/circadian disorders; recent night shift or ≥3 time-zone travel
  5. Prohibited medications (e.g., beta-blockers, systemic >10 mg prednisone-equivalent ≥7 days, melatonin/psychotropics; recent G-CSF/GM-CSF/CXCR4 inhibitor use)
  6. Severe allergy to G-CSF or components
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    Morning G-CSF Dosing

    7.5 μg/kg subcutaneous once daily for 4-5 days at 08:00 ± 15 min

    Drug: G-CSF (Granulocyte colony-stimulating factor)

  • Experimental
    Evening G-CSF Dosing

    7.5 μg/kg subcutaneous once daily for 4-5 days at 20:00 ± 15 min

    Drug: G-CSF (Granulocyte colony-stimulating factor)

Interventions

06

What researchers measure

Primary outcomes

  1. Peripheral Blood CD34+ Cell Count before the first apheresis session

    Peripheral blood CD34+ cell count (cells/μL) measured at a fixed clock time of 11:30 (±15 minutes), after the fourth G-CSF dose and immediately before the first apheresis session, scheduled to begin at 12:00 in both treatment groups. CD34+ cell counts will be determined using standardized flow cytometry procedures.

    Time frame: After the fourth G-CSF dose, immediately before the first apheresis session (11:30 ±15 minutes).

Secondary outcomes

  1. Peripheral Blood CD34+ Cell Count 12 Hours After the Third G-CSF Dose

    Peripheral blood CD34+ cell count (cells/μL) measured 12 (±1) hours after the third G-CSF dose, before any apheresis procedure. CD34+ cells will be enumerated using standardized flow cytometry procedures.

    Time frame: 12 (±1) hours after the third G-CSF dose, before the first apheresis session.

  2. CD34+ Cell Yield During the First Apheresis Session

    Total number of CD34+ cells collected during the first apheresis session, normalized to donor body weight and expressed as ×10⁶ CD34+ cells/kg.

    Time frame: At completion of the first apheresis session following the fourth G-CSF dose.

  3. Peripheral Blood CD34+ Cell Count before the second apheresis session

    Peripheral blood CD34+ cell count (cells/μL) measured at a fixed clock time of 11:30 (±15 minutes), after the fifth G-CSF dose and immediately before the second apheresis session, scheduled to begin at 12:00 in both treatment groups. CD34+ cell counts will be determined using standardized flow cytometry procedures.

    Time frame: After the fifth G-CSF dose, immediately before the second apheresis session (11:30 ±15 minutes).

  4. Peripheral Blood CD34+ Cell Count 12 Hours After the Fourth G-CSF Dose

    Peripheral blood CD34+ cell count (cells/μL) measured 12 (±1) hours after the fourth G-CSF dose using standardized flow cytometry procedures.

    Time frame: 12 (±1) hours after the fourth G-CSF dose, regardless of the timing of the first apheresis session.

  5. G-CSF Dose Escalation

    Proportion of donors requiring an increase in the daily G-CSF dose above the protocol-specified 10 μg/kg/day because of inadequate mobilization or insufficient CD34+ cell yield. Routine administration of an additional fifth G-CSF dose without increasing the daily dose will not be classified as dose escalation.

    Time frame: From the first apheresis session until completion of the final apheresis session, typically within 2 consecutive days and up to 3 consecutive days.

  6. Proportion of Donors Requiring Plerixafor Rescue Mobilization

    Proportion of donors receiving plerixafor rescue mobilization because of inadequate peripheral blood CD34+ mobilization or insufficient collection yield, according to prespecified rescue criteria.

    Time frame: From the first G-CSF dose through completion of the final apheresis session, typically within 2 days and up to 3 consecutive days of apheresis.

  7. Incidence of Adverse Events in Healthy Donors

    Incidence and severity of adverse events associated with G-CSF mobilization, apheresis procedures, and rescue mobilization, including bone pain, headache, fatigue, citrate-related reactions, and vascular access complications. Adverse events will be assessed according to the protocol-specified grading system.

    Time frame: From the first G-CSF dose through 30 days after the final apheresis session.

  8. Time to Neutrophil Engraftment After Transplantation

    Time from stem cell infusion to neutrophil engraftment in transplant recipients, defined as the first of three consecutive days with an absolute neutrophil count ≥0.5 × 10⁹/L. Death before engraftment will be treated as a competing event in exploratory analyses.

    Time frame: From transplantation (Day 0) through Day 100 after transplantation.

  9. Time to Platelet Engraftment After Transplantation

    Time from stem cell infusion to platelet engraftment in transplant recipients, defined as the first of seven consecutive days with a platelet count ≥20 × 10⁹/L without platelet transfusion during the preceding seven days. Death before engraftment will be treated as a competing event.

    Time frame: From transplantation (Day 0) through Day 100 after transplantation.

  10. Cumulative Incidence of De Novo Grade II-IV and III-IV Acute Graft-versus-Host Disease

    Cumulative incidence of newly occurring grade II-IV and grade III-IV acute graft-versus-host disease (aGVHD) among transplant recipients, assessed using prespecified standard grading criteria. Competing events will be handled using competing-risk methods.

    Time frame: From transplantation (Day 0) through Day 100 after transplantation.

  11. Total Number of Apheresis Sessions per Donor

    Total number of apheresis sessions performed for each donor during the mobilization and collection period.

    Time frame: From the first apheresis session through completion of the final apheresis session, typically within 2 consecutive days and up to 3 consecutive days.

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared because the study involves healthy donors and contains potentially identifiable information. De-identified, aggregate results will be reported in publications and presentations. Reasonable requests for additional information may be considered by the study team on a case-by-case basis, subject to ethics approval and data governance requirements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: start Mar 2026 → Nov 2026 and completion Mar 2027 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2026
First posted
Feb 20, 2026
StartEst.
Nov 1, 2026was Mar 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Nov 1, 2027was Mar 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 1, 2026→Nov 1, 2026
Oct 29, 2026
Study completion
Mar 30, 2027→Nov 1, 2027
Oct 29, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedPre-Apheresis Peripheral Blood CD34+ Cell Count before the first apheresis sessionTime frame: On the day of first apheresis: approximately 12 (±1) hours after the final G-CSF dose and within 60 minutes prior to apheresis start. → After the fourth G-CSF dose, immediately before the first apheresis session (11:30 ±15 minutes).
Oct 29, 2026
Secondary outcomes
11 added
What changed in the outcomes
  • AddedPeripheral Blood CD34+ Cell Count 12 Hours After the Third G-CSF DoseTime frame: 12 (±1) hours after the third G-CSF dose, before the first apheresis session.
  • AddedCD34+ Cell Yield During the First Apheresis SessionTime frame: At completion of the first apheresis session following the fourth G-CSF dose.
  • AddedPeripheral Blood CD34+ Cell Count before the second apheresis sessionTime frame: After the fifth G-CSF dose, immediately before the second apheresis session (11:30 ±15 minutes).
  • AddedPeripheral Blood CD34+ Cell Count 12 Hours After the Fourth G-CSF DoseTime frame: 12 (±1) hours after the fourth G-CSF dose, regardless of the timing of the first apheresis session.
  • AddedG-CSF Dose EscalationTime frame: From the first apheresis session until completion of the final apheresis session, typically within 2 consecutive days and up to 3 consecutive days.
  • AddedProportion of Donors Requiring Plerixafor Rescue MobilizationTime frame: From the first G-CSF dose through completion of the final apheresis session, typically within 2 days and up to 3 consecutive days of apheresis.
  • AddedIncidence of Adverse Events in Healthy DonorsTime frame: From the first G-CSF dose through 30 days after the final apheresis session.
  • AddedTime to Neutrophil Engraftment After TransplantationTime frame: From transplantation (Day 0) through Day 100 after transplantation.
  • AddedTime to Platelet Engraftment After TransplantationTime frame: From transplantation (Day 0) through Day 100 after transplantation.
  • AddedCumulative Incidence of De Novo Grade II-IV and III-IV Acute Graft-versus-Host DiseaseTime frame: From transplantation (Day 0) through Day 100 after transplantation.
  • AddedTotal Number of Apheresis Sessions per DonorTime frame: From the first apheresis session through completion of the final apheresis session, typically within 2 consecutive days and up to 3 consecutive days.
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Start date Mar 1, 2026→Nov 1, 2026
    Study completion Mar 30, 2027→Nov 1, 2027
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPre-Apheresis Peripheral Blood CD34+ Cell Count before the first apheresis sessionTime frame: On the day of first apheresis: approximately 12 (±1) hours after the final G-CSF dose and within 60 minutes prior to apheresis start. → After the fourth G-CSF dose, immediately before the first apheresis session (11:30 ±15 minutes).
    Secondary outcomes 11 added
    What changed in the outcomes
    • AddedPeripheral Blood CD34+ Cell Count 12 Hours After the Third G-CSF DoseTime frame: 12 (±1) hours after the third G-CSF dose, before the first apheresis session.
    • AddedCD34+ Cell Yield During the First Apheresis SessionTime frame: At completion of the first apheresis session following the fourth G-CSF dose.
    • AddedPeripheral Blood CD34+ Cell Count before the second apheresis sessionTime frame: After the fifth G-CSF dose, immediately before the second apheresis session (11:30 ±15 minutes).
    • AddedPeripheral Blood CD34+ Cell Count 12 Hours After the Fourth G-CSF DoseTime frame: 12 (±1) hours after the fourth G-CSF dose, regardless of the timing of the first apheresis session.
    • AddedG-CSF Dose EscalationTime frame: From the first apheresis session until completion of the final apheresis session, typically within 2 consecutive days and up to 3 consecutive days.
    • AddedProportion of Donors Requiring Plerixafor Rescue MobilizationTime frame: From the first G-CSF dose through completion of the final apheresis session, typically within 2 days and up to 3 consecutive days of apheresis.
    • AddedIncidence of Adverse Events in Healthy DonorsTime frame: From the first G-CSF dose through 30 days after the final apheresis session.
    • AddedTime to Neutrophil Engraftment After TransplantationTime frame: From transplantation (Day 0) through Day 100 after transplantation.
    • AddedTime to Platelet Engraftment After TransplantationTime frame: From transplantation (Day 0) through Day 100 after transplantation.
    • AddedCumulative Incidence of De Novo Grade II-IV and III-IV Acute Graft-versus-Host DiseaseTime frame: From transplantation (Day 0) through Day 100 after transplantation.
    • AddedTotal Number of Apheresis Sessions per DonorTime frame: From the first apheresis session through completion of the final apheresis session, typically within 2 consecutive days and up to 3 consecutive days.
    + 4 other changes: verification date, description, design details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07423728
Responsible party
Yanmin Zhao (professor, First Affiliated Hospital of Zhejiang University) — Principal investigator
First posted
Feb 20, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Hengwei Wu, MD
Contact
cctv3194495@163.com
+8619858162455

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Granulocyte Colony-Stimulating Factor

Start the discussion